The race against resistance: Reinforcing India's anti-infective arsenal

Antimicrobial resistance (AMR) is a global health crisis, threatening to undo decades of medical progress and plunge us into a post-antibiotic era where even minor infections could prove fatal. This silent pandemic demands immediate and decisive action from all stakeholders before we are left vulnerable to previously treatable infections. The alarming rise of drug-resistant infections, coupled with a stagnant pipeline of new treatment options, paints a grim picture for the future of healthcare.

The statistics underscore the urgency of this situation: the WHO estimates that by 2050, AMR could claim a staggering 10 million lives annually. This exponential rise in AMR translates to increased mortality rates, prolonged hospital stays, and a significant burden on healthcare systems globally, pushing them towards a breaking point.

While this crisis affects the world over, India faces a particularly daunting challenge due to its high burden of infectious diseases, dense population, and existing healthcare infrastructure challenges. The severity of the AMR crisis in India is highlighted by concerning data: in 2019, 4.95 million people who died in the country suffered from drug-resistant infections, with AMR directly causing 1.27 million of those deaths. Existing treatments are becoming increasingly ineffective against resistant strains, fuelled by the overuse and misuse of antibiotics, often driven by factors such as self-medication and inadequate access to qualified healthcare professionals. This diminishing efficacy underscores the urgent need for new, effective anti-infectives to replenish and strengthen our arsenal against this growing threat.
Unfortunately, developing novel antibiotics has become commercially unattractive for many pharmaceutical companies due to the lengthy, complex, and expensive research and development process. This has resulted in a "dry pipeline" of new antibiotics, leaving us ill-prepared to face the looming threat of AMR.

While research efforts in India, such as exploring novel antibiotic adjuvants, offer a glimmer of hope, translating these discoveries into widely available treatment options requires a concerted effort. Prioritizing research and development in anti-infectives are paramount, including incentivizing pharmaceutical companies through tax breaks, grants, and other financial support mechanisms to encourage investment in this critical area.

Equally important is fostering collaborations between academic institutions, research organizations, and the pharmaceutical industry to leverage expertise and resources, accelerating the development and availability of new antibiotics. International collaboration can also play a vital role in sharing knowledge, data, and resources to combat this global threat more effectively.

The fight against AMR in India is critical and urgent. Reinforcing our anti-infective toolkit through increased research, strategic collaborations, and policy interventions is crucial. All stakeholders must unite to implement antibiotic stewardship, improve public awareness, and invest in innovative treatments. By acting decisively now, we can preserve the efficacy of antibiotics and better prepare for the evolving threat of AMR.

(Author: Dr Abhishek Bhargav, Cardiologist & Diabetologist , Sujay Hospital, Mumbai)